Anithrombotic prevention in vascular disease: Bases for a new strategy in antithrombotic therapy

Thrombosis Journal

Volumn 5, Issue , 2007, Pages

  Altman, Raul ^a,b  

^a Centro de Trombosis de Buenos Aires   (Argentina)

^b UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CELECOXIB; CLOPIDOGREL; CORTICOSTEROID; DABIGATRAN; DALTEPARIN; ENOXAPARIN; GLUCOCORTICOID; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MELAGATRAN; MELOXICAM; PLACEBO; PRASUGREL; PREDNISONE; RIVAROXABAN; ROFECOXIB; THROMBOPLASTIN; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ATHEROMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; HEART MUSCLE ISCHEMIA; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; RISK REDUCTION; SINGLE DRUG DOSE; THROMBOGENESIS; THROMBOSIS; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

EID: 35548971981     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-5-11     Document Type: Editorial

References (62)

1. Altman R Scazziota AS Herrera ML Gonzalez C Thrombin generation by activated factor VII on platelet activated by different agonists Extending the cell-based model of hemostasis Thromb J 2006, 4:5.
2. Aledort LM Recombinant factor VII: Ia is a pan-hemostatic agent? Thromb Haemost 2000, 83: 637-638. 10823252
3. Bhatt DL Fox KA Hacke W Berger PB Black HR Boden WE Cacoub P Cohen EA Creager MA Easton JD Flather MD Haffner SM Hamm CW Hankey GJ Johnston SC Mak KH Mas JL Montalescot G Pearson TA Steg PG Steinhubl SR Weber MA Brennan DM Fabry-Ribaudo L Booth J Topol EJ CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 2006, 354:1706-1717. 10.1056/ NEJMoa060989 16531616
4. Ballew KA Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Evid Based Med 2006, 11:143. 10.1136/ebm.11.5.143 17213145
5. Fisher M Lees K Norris JW Barnett HJ CHARISMA: The Antiplatelet Saga Continues Stroke 2006, 37:2428-2429. 10.1161/01.STR.0000236037.87109.fc 16857946
6. Mohler ER III Atherothrombosis - Wave Goodbye to Combined Anticoagulation and Antiplatelet Therapy? N Engl J Med 2007, 357:293-296. 10.1056/NEJMe078106 17634465
7. Doggrell SA Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction Expert Opin Pharmacother 2003, 4:587-590. 10.1517/14656566.4.4.587 12667121
8. Fox KA Mehta SR Peters R Zhao F Lakkis N Gersh BJ Yusuf S for Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trial Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial Circulation 2004, 110:1202-1208. 10.1161/01.CIR.0000140675.85342.1B 15313956
9. Eikelboom JW Hirsh J Bleeding and Management of Bleeding Eur Heart J 2006, 8:G38-45. 10.1093/eurheartj/sul054
10. Colman RW Are hemostasis and thrombosis two sides of the same coin? J Exp Med 2006, 203:493-495. 10.1084/jem.20060217 16533890
11. Renne T Pozgajova M Gruner S Schuh K Pauer HU Burfeind P Gailani D Nieswandt B Defective thrombus formation in mice lacking coagulation factor XII J Exp Med 2005, 202:271-281. 10.1084/jem.20050664 16009717
12. Moreno PR Purushothaman KR Fuster V Echeverri D Truszczynska H Sharma SK Badimon JJ O'Connor WN Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: Implications for plaque vulnerability Circulation 2004, 110:2032-2038. 10.1161/ 01.CIR.0000143233.87854.23 15451780
13. Furie B Furie BC In vivo thrombus formation J Thromb Haemost 2007, 5(Suppl 1):12-17. 10.1111/j.1538-7836.2007.02482.x 17635703
14. Day SM Reeve JL Pedersen B Farris DM Myers DD Im M Wakefield TW Mackman N Fay WP Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall Blood 2005, 105:192-8. 10.1182/ blood-2004-06-2225 15339841
15. Hoffman M Whinna HC Monroe DM Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs J Thromb Haemost 2006, 4:2092-2093. 10.1111/j.1538-7836.2006.02085.x 16961625
16. Bach RR Tissue factor encryption Arterioscl Thromb Vasc Biol 2006, 26:456-461. 10.1161/01.ATV.0000202656.53964.04 16397140
17. Hemker HC Béguin S Thrombin generation in plasma: Its assessment via the endogenous thrombin potential Thromb Haemost 1995, 74:134-138. 8578446
18. Niemetz J Fallon JT Harrington E Hathcock J Rapid generation of thrombin by atheroma and platelets J Thromb Haemost 2004, 2:321-326. 10.1111/ j.1538-7836.2004.00551.x 14995996
19. Schroeder V Chatterjee T Mehta H Windecker S Pham T Devantay N Meier B Kohler HP Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography Thromb Haemost 2002, 88:1020-1025. 12529754
20. Gurfinkel E Altman R Scazziota A Rouvier J Mautner B Importance of thrombosis and thrombolysis in silent ischaemia: Comparison of patients with acute myocardial infarction and unstable angina Br Heart J 1994, 71:151-155. 483635 8130023 10.1136/hrt.71.2.151
21. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators Dose-Ranging Trial of Enoxaparin for Unstable Angina: Results of TIMI 11A J Am Coll Cardiol 1997, 29:1474-1414. 10.1016/S0735-1097(97)00094-6 9180107
22. FRISC Study Group Low molecular weight heparin (Fragmin®) during instability in coronary artery disease (FRISC) Lancet 1996, 347:561-568. 8596317
23. Eriksson BI Arfwidsson AC Frison L Eriksson UG Bylock A Kalebo P Fager G Gustafsson D A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery Thromb Haemost 2002, 87:231-237. 11858482
24. Albers GW Diener HC Frison L Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial JAMA 2005, 293:690-698. 10.1001/jama.293.6.690 15701910
25. Petersen P Grind M Adler J SPORTIF II Investigators Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation SPORTIF II: A dose-guiding, tolerability, and safety study J Am Coll Cardiol 2003, 41:1445-1451. 10.1016/S0735-1097(03)00255-9 12742279
26. Eriksson BI Dahl OE Büller HR Hettiarachchi R Rosencher N Bravo M-L Ahnfelt L Piovella F Stangier J Kälebo P Reilly P A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial J Thromb Haemost 2005, 3:103-111. 10.1111/j.1538-7836.2004.01100.x 15634273
27. Turpie AGG Fisher WD Bauer KA Kwong LM Irwin MW Kälebo P Misselwitz F Gent M For the Odixa-Knee study group BAY 59-7939: An oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study J Thromb Haemost 2005, 3:247-2486. 10.1111/j.1538-7836.2005.01602.x 16241946
28. Eriksson BI Borris L Dahl OE Haas S Huisman MV Kakkar AK Misselwitz F Kälebo P Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement J Thromb Haemost 2006, 4:121-128. 10.1111/j.1538-7836.2005.01657.x 16409461
29. Eriksson BI Borris LC Dahl OE Haas S Huisman MV Kakkar AK Muehlhofer E Dierig C Misselwitz F Kalebo P ODIXa-HIP Study Investigators A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement Circulation 2006, 114:2374-2381. 10.1161/CIRCULATIONAHA.106.642074 17116766
30. Esmon CT The protein C pathway Chest 2003 124, (3 Suppl):26S-32S. 10.1378/chest.124.3_suppl.26S 12970121
31. Esmon CT Inflammation and the activated protein C anticoagulant pathway Semin Thromb Hemost 2006, 32, (Suppl 1):49-60. 10.1055/s-2006-939554 16673266
32. Spronk HM van der Voort D Ten Cate H Blood coagulation and the risk of atherothrombosis: A complex relationship Thromb J 2004, 2(12):538274-15574198. 10.1186/1477-9560-2-12
33. Esmon CT Crosstalk between inflammation and thrombosis Maturitas 2004, 47:305-314. 10.1016/j.maturitas.2003.10.015 15063484
34. Segev A Strauss BH Tan M Constance C Langer A Goodman SG Canadian Acute Coronary Syndromes Registries Investigators Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: Insights from the Canadian Acute Coronary Syndrome Registries Am Heart J 2005, 150:690-694. 10.1016/j.ahj.2004.11.012 16209967
35. Campbell CL Smyth S Montalescot G Steinhubl SR Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review JAMA 2007, 297:2018-2024. 10.1001/jama.297.18.2018 17488967
36. Yusuf S Zhao F Mehta SR Chrolavicius S Tognoni G Fox KK The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 2001, 345:494-502. 10.1056/NEJMoa010746 11519503
37. Peters RJ Mehta SR Fox KA Zhao F Lewis BS Kopecky SL Diaz R Commerford PJ Valentin V Yusuf S Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Circulation 2003, 108:1682-1687. 10.1161/01.CIR.0000091201.39590.CB 14504182
38. Steinhubl SR Berger PB Mann JT 3rd Fry ET DeLago A Wilmer C Topol EJ CREDO Investigators Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial JAMA 2002, 288:2411-2420. Erratum in: JAMA. 2003; 289:987. 10.1001/ jama.288.19.2411 12435254
39. Wiviott SD Antman EM Winters KJ Weerakkody G Murphy SA Behounek BD Carney RJ Lazzam C McKay RG McCabe CH Braunwald E JUMBO-TIMI 26 Investigators Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial Circulation 2005, 111:3366-3373. 10.1161/CIRCULATIONAHA.104.502815 15967851
40. Serebruany VL Midei MG Meilman H Malinin AI Lowry DR Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: The subset from the JUMBO study Postgrad Med J 2006, 82:404-10. 10.1136/pgmj.2006.047696 16754711
41. Rhen T Cidlowski JA Antiinflammatory action of glucocorticoids - new mechanisms for old drugs N Engl J Med 2005, 353:1711-1723. 10.1056/ NEJMra050541 16236742
42. Mackman N Role of Tissue Factor in Hemostasis, Thrombosis, and Vascular Development Arterioscler Thromb Vasc Biol 2004, 24:1015-1022. 10.1161/ 01.ATV.0000130465.23430.74 15117736
43. Annex BH Denning SM Channon KM Sketch MH Stack RS Morrissey JH Peters KG Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes Circulation 1995, 91:619-622. 7828284
44. Vojacek J Dusek J Bis J Stasek J Blazek M Plasma tissue factor in coronary artery disease. Further step to the understanding of the basic mechanisms of coronary artery thrombosis Physiol Res 2007 Jan 2. 17223726
45. Versaci F Gaspardone A Tomai F Ribichini F Russo P Proietti I Ghini AS Ferrero V Chiariello L Gioffre PA Romeo F Crea F Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation Study Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study) J Am Coll Cardiol 2002, 40:1935-1942. 10.1016/S0735-1097(02)02562-7 12475452
46. Schacke H Docke WD Asadullah K Mechanisms involved in the side effects of glucocorticoids Pharmacol Ther 2002, 96:23-43. 10.1016/ S0163-7258(02)00297-8 12441176
47. Altman R Luciardi HL Muntaner J Del Rio F Berman SG Lopez R Gonzalez C Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation. The Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study Circulation 2002, 106:191-195. 10.1161/ 01.CIR.0000021599.56755.A1 12105157
48. Chello M Anselmi A Spadaccio C Patti G Goffredo C Di Sciascio G Covino E Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery Ann Thorac Surg 2007, 83:1374-1380. 10.1016/j.athoracsur.2006.10.065 17383342
49. Ray KK Cannon CP Lipid-independent Pleiotropic Effects of Statins in the Management of Acute Coronary Syndromes Curr Treat Options Cardiovasc Med 2007, 9:46-51. 17378975
50. Wu YS Hu YY Yang RF Wang Z Wei YY The matrix metalloproteinases as pharmacological target in osteoarthritis: Statins may be of therapeutic benefit Med Hypotheses 2007, 69:557-559. 17360129 17360129 10.1016/ j.mehy.2007.01.042
51. Pasceri V Patti G Nusca A Pristipino C Richichi G Di Sciascio G ARMYDA Investigators Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study Circulation 2004, 110:674-678. 10.1161/01.CIR.0000137828.06205.87 15277322
52. Patti G Pasceri V Colonna G Miglionico M Fischetti D Sardella G Montinaro A Di Sciascio G Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention J Am Coll Cardiol 2007, 49:1272-1278. 10.1016/ j.jacc.2007.02.025 17394957
53. Angiolillo DJ Shoemaker SB Desai B Yuan H Charlton RK Bernardo E Zenni MM Guzman LA Bass TA Costa MA Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study Circulation 2007, 115:708-716. 10.1161/CIRCULATIONAHA.106.667741 17261652
54. Alexander KP Chen AY Roe MT Newby LK Gibson CM Allen-LaPointe NM Pollack C Gibler WB Ohman EM Peterson ED CRUSADE Investigators Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes JAMA 2005, 294:3108-3116. 10.1001/ jama.294.24.3108 16380591
55. Mukherjee D Nissen SE Topol EJ Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 2001, 286:954-959. 10.1001/ jama.286.8.954 11509060
56. Fitzgerald GA Coxibs and cardiovascular disease N Engl J Med 2004, 351:1709-1711. 10.1056/NEJMp048288 15470192
57. Antman EM Bennett JS Daugherty A Furberg C Roberts H Taubert KA American Heart Association Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association Circulation 2007, 115:1634-1642. 10.1161/ CIRCULATIONAHA.106.181424 17325246
58. Sabatine MS Morrow DA Jablonski KA Rice MM Warnica JW Domanski MJ Hsia J Gersh BJ Rifai N Ridker PM Pfeffer MA Braunwald E PEACE Investigators Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease Circulation 2007, 115:1528-1536. 10.1161/ CIRCULATIONAHA.106.649939 17372173
59. Bogaty P Brophy JM Noel M Boyer L Simard S Bertrand F Dagenais GR Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: A randomized placebo-controlled study Circulation 2004, 110:934-939. 10.1161/01.CIR.0000139338.12464.5F 15302800
60. Monakier D Mates M Klutstein MW Balkin JA Rudensky B Meerkin D Tzivoni D Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes Chest 2004, 125:1610-1605. 10.1378/chest.125.5.1610 15136366
61. Koo BK Kim YS Park KW Yang HM Kwon DA Chung JW Hahn JY Lee HY Park JS Kang HJ Cho YS Youn TJ Chung WY Chae IH Choi DJ Oh BH Park YB Kim HS Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): An open-label randomised controlled study Lancet 2007, 370:567-74. 10.1016/S0140-6736(07)61295-1 17707751
62. Eikelboom JW Mehta SR Anand SS Xie C Fox KA Yusuf S Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 2006, 114:774-782. 10.1161/CIRCULATIONAHA.106.612812 16908769